Good day, ladies and gentlemen, and welcome to the Altimmune Inc. Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. To ask a question during the session, you will need to press star one one on your telephone. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, Rich Eisenstadt, Chief Financial Officer of Altimmune. Rich, you may begin. Thank you, Gigi. Good morning, everyone. Thank you for participating in Altimmune's second quarter 2023 financial results and business update conference call. Members of the Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer, Scot Roberts, our Chief Scientific Officer, and M. Scott Harris, our Chief Medical Officer. Following the prepared remarks, we will hold a question and answer session. A press release with our second quarter 2023 financial results was issued this morning and can be found on the investor relations section of the company's website. Before we begin, I'd like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a discussion of some of the risks and factors that could affect the company's future results and operations, please see the risk factors and other cautionary statements contained in the company's filings with the SEC. I would also direct you to read the forward-looking statement disclosure in our press release issued this morning and now available on our website. Any statements made on this conference call speak only as of today's date, Thursday, August 10th, 2023, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio replay on Altimmune's website. With that, I will now turn the call over to Dr. Vipin Garg, our Chief Executive Officer. Thank you, Rich. Good morning, everyone. We appreciate you joining us today for a discussion of our second quarter 2023 financial results and business update. We are excited about the progress of our lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist in development for both obesity and NASH. We recently announced the initiation of our phase II-B IMPACT biopsy-driven trial to evaluate the efficacy and safety of pemvidutide in NASH. Given the compelling 12 and 24-week data from our phase I-B trials in subjects with NAFLD, we expect to achieve significant rates of NASH resolution and fibrosis improvement at data readout from the IMPACT trial, which is anticipated in Q1 2025. The data from our NAFLD trial demonstrated a greater than 75% relative reduction in liver fat at 24 weeks, with over 50% of subjects achieving the high bar of normalization of liver fat in the 1.8 mg dose group. Subjects also had a mean weight loss of up to 7.2% at 24 weeks in the 1.8 mg dose group, with weight loss continuing at the end of treatment. We also achieved significant reduction in serum ALT and MRI-based corrected T1 imaging, both important markers of NASH improvement. We believe that a robust reduction in NASH activity, combined with fibrosis improvement and meaningful weight loss, will be essential for a competitive product in the NASH marketplace. With regards to obesity, we look forward to reporting top-line 48-week data from our phase II MOMENTUM trial in the fourth quarter of this year. The MOMENTUM interim results of 160 subjects reported earlier this year showed weight loss of 10.7% at the 2.4 mg dose and 9.4% at the 1.8 mg dose, compared to a 1% weight loss in subjects receiving placebo after only 24 weeks of treatment. These robust reductions in body weight, together with the effects of pemvidutide on serum lipids and blood pressure without cardiovascular safety signals, suggest that if approved, pemvidutide can be an important treatment option for patients with obesity, especially those with NAFLD or dyslipidemia. It's important to point out that these two comorbidities are prevalent in 60%-75% of the obesity population. Finally, we have to have a data readout from our phase II clinical trial of HepTcell in chronic hepatitis B in the first quarter of 2024. Recall that this trial is designed to show evidence of antiviral effects against hepatitis B virus and establish the role of HepTcell in combination therapy for the treatment of this unmet need. We're excited about the progress of pemvidutide and HepTcell and the upcoming results of these ongoing trials. With that, I now turn the call over to our Chief Medical Officer, Dr. Scott Harris, to discuss our clinical plans. Scott? Thank you, Vipin, and good morning, everyone. First, let me tell you about the initiation of our IMPACT phase IIb NASH trial. This biopsy-driven trial is being conducted at approximately 60 sites in the United States with Dr. Stephen Harrison, Medical Director, Pinnacle Clinical Research, and Adjunct Professor of Medicine, University of Oxford, serving as the principal investigator. We are planning for approximately 190 subjects, both with and without diabetes, to be enrolled. Subjects will be randomized to pemvidutide 1.2 mgs, pemvidutide 1.8 mgs, or placebo in a 1 to 2 to 2 ratio, and will be stratified for fibrosis stage in the presence or absence of diabetes. Therefore, approximately 38 subjects are expected to receive pemvidutide 1.2 mgs, 76 subjects, pemvidutide 1.8 mgs, and 76 subjects, placebo. To be eligible for study participation, subjects will be required to have a BMI of at least 27 kg per meter squared, a liver fat content by MRI-PDFF of at least 8%, and a NAFLD activity score of at least four on a pretreatment liver biopsy. They're also expected to have either F2 or F3 fibrosis, with at least 50% of subjects required to have F3 fibrosis. The primary endpoints of the IMPACT trial will be the dual endpoints of achieving either NASH resolution with no worsening of fibrosis or fibrosis improvement with no worsening of NASH, with the primary treatment comparison being the 1.8 mg dose versus placebo. Secondary endpoints will include achievement of both NASH resolution and fibrosis improvement, liver fat reduction by MRI-PDFF, corrected T1 or CT1 response rate, serum lipids, and non-invasive biomarkers of disease activity. Importantly, weight loss will also be assessed as a key endpoint. All endpoints will be evaluated at week 24 of treatment, and subjects will continue to be dosed and followed for an additional 24 weeks to a total of 48 weeks for safety and additional biomarker responses. We plan to employ a consensus read between two pathologists, with a third who will adjudicate if consensus is not reached. A plan has also been developed to correlate non-invasive tests with NASH resolution and fibrosis improvement, the biopsy endpoints, and to commence discussions with FDA regarding the use of these biomarkers as primary endpoints in phase III. We anticipate reporting top-line results at 24 weeks in the first quarter of 2025. Now, let me talk about the phase II MOMENTUM trial of pemvidutide in obesity. The trial was designed to enroll approximately 320 subjects without diabetes, but with obesity, or overweight, with at least one obesity-associated comorbidity. Dr. Louis Aronne from Weill Cornell Medicine, a leading authority in obesity and obesity clinical trials, is serving as the principal investigators. Subjects were randomized 1 to 1 to 1 to 1 to pemvidutide 1.2 mg, pemvidutide 1.8 mg, pemvidutide 2.4 mg, or placebo, administered weekly for 48 weeks in conjunction with diet and exercise. Prespecified interim analysis was performed when 160 subjects completed 24 weeks of treatment. Weight loss of 10.7% at the 2.4 mg dose and 9.4% at the 1.8 mg dose was achieved, compared to a weight loss of 1% in subjects receiving placebo. Approximately 50% of subjects achieved at least 10% weight loss, and approximately 20% of subjects achieved at least 15% weight loss by week 24 at the 2.4 and 1.8 mg doses. Significant improvements or positive trends in cardiometabolic risk factors were observed. Importantly, these effects were achieved without arrhythmias, clinically meaningful heart rate increases, or other safety signals. We look forward to the top-line 48-week results from the MOMENTUM trial in the fourth quarter of this year. We expect to see continued weight loss beyond the double-digit levels noted in our 24-week interim analysis. Other top-line readout parameters will include subject disposition, adverse events, vital signs, serum lipids, and glucose control. Also, as we have previously announced, we have completed enrollment in our phase II multicenter clinical trial of HepTcell in patients with chronic hepatitis B. Chronic hepatitis B continues to represent a serious unmet need in the United States and worldwide, and represents a significant commercial opportunity. HepTcell is an immunotherapeutic designed to activate T-cells to fight the hepatitis B virus infection. The HepTcell trial was designed to enroll approximately 80 subjects with an active chronic hepatitis B and low hepatitis B surface antigen. The primary endpoint of the trial is a 1-log reduction or clearance of the hepatitis B surface antigen. We expect to announce the results of this trial in the first quarter of 2024, once all subjects complete the six-month treatment period. It's generally believed that an effective therapy for chronic hepatitis B infection will require both direct-acting antivirals and immunotherapy. We believe that HepTcell is highly differentiated and may provide for a functional cure of chronic hepatitis B infection with combined with novel direct-acting antivirals. I'll now turn the call over to Rich Eisenstadt to give an update on our third quarter financial results. Rich? Thank you, Scott, and good morning again. For today's call, I'll be providing a brief update on Altimmune's second quarter 2023 financial and operating results. More comprehensive information will be available on our Form 10-Q, to be followed with the SEC later today. Altimmune ended the second quarter of 2023 with approximately $160 million of cash, cash equivalents, and short-term investments, compared to $184.9 million at the end of 2022. Research and development expenses were $13.3 million in the second quarter of 2023, compared to $16 million in the same period in 2022. Approximately $7.4 million of this total for the 2Q 2023 were direct expenses for the conduct of our clinical programs, including $5.6 million in direct costs related to development activities for pemvidutide, and $1.8 million in direct costs related to development activities for HepTcell. General administrative expenses were $4.8 million for the three months ended June 30, 2023, compared to $4.4 million in the same period in 2022. The change is primarily attributable to increased stock compensation and other labor-related expenses. Approximately $3 million of our quarterly operating expense is non-cash expense, primarily stock compensation. Interest income was $1.8 million in the 2Q 2023, compared to $300,000 in the same period of 2022. Net loss for the three months ended June 30th, 2023, was $16.1 million, or $0.32 net loss per share, compared to net loss of $20.1 million or $0.42 net loss per share for the second quarter of 2022. We estimate that our existing cash funds us through the 24-week biopsy results from our IMPACT phase IIb NASH trial, expected in the first quarter of 2025. Our financing also funds completion of the 48-week MOMENTUM trial and the HepTcell trial. I will now turn it back over to Vipin for his closing remarks. Vipin? Operator, that concludes our formal remarks, and we would like to open the lines to take questions. Could you please instruct the audience on the Q&A procedure? Thank you. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Seamus Fernandez from Guggenheim. Hi, there. This is Alana, on for Seamus from Guggenheim. Thanks for taking our question. We were just curious, as far as your expectations for weight loss at 48 weeks, are you still targeting mid to upper teens? Secondly, any thoughts on what Merck presented with respect to their GLP glucagon at EASD recently? Thank you. Sure, Alana. Good morning. Scott, do you want to take that? Yes. Thank you for the question. Yes, we still are expecting weight loss in the mid to upper teens. We think that in view of the SELECT readouts, which showed that to be associated with a significant reduction in cardiovascular risk, that's a, a very significant point to achieve. With regards to SELECT, I would point out that that was achieved with GLP-1 monotherapy alone. With the glucagon effects, we believe that with the reduction in serum lipids and also hepatic fat, that we can achieve even better results than those achieved by semaglutide in that trial. With regards to Merck, we believe that the findings validate our our continued hypothesis and results that glucagon is extremely important for reducing liver fat. We were happy to see confirmation of that information. Several things I would point out about that trial was, number one, they had to go through a significant titration period. We're not doing that. We have no titration at the two doses that we're employing in our upcoming trial, NASH trial. The second is, that compound has also been associated with significant heart rate increases, which, as I mentioned in my opening remarks, those have not been seen in our program. Great. Thank you. Thank you. One moment for our next question. Our next question comes from the line of Yasmeen Rahimi from Piper Sandler. Good morning, team, and thank you so much for all the great updates. I think this morning, as, as you know, the SELECT data this week has really emphasized how the demand for new novel therapies for obesity continue to increase. I think we saw also this morning another acquisition by Novo. This raises the question, sort of, if you could just kind of give us an update on how the M&A interest is evolving. I think we have seen in the last month, two acquisitions of therapies of where they bring broader novelty and that it's not just about weight loss. I would love to get an update on how M&A interest is, is, is, is growing, and what do you expect the impact on SELECT will be in your discussions with potential partners around obesity? Then secondly, there are two additional key readouts, upcoming in the first half of 2024, biopsy data from tirzepatide from as well as, the GLP-1 glucagon compound from BI and Zealand. Would love to hear your thoughts on how you're thinking about how those results could provide color or detail or translation or anything around that. I think a lot of our clients may not realizing that those two readouts are really key. Would love to hear if you could tackle M&A, tackle what do you expect to see in these two biopsy readouts with two incretins in the first half of 2024. I'll jump back into the queue. Thank you. Yeah. Thank you, Yas. Thank you for the questions. Let me take the M&A question, and then I'll turn it over to Scott Harris to talk about the data coming out in the first half of next year. As you know, we've been saying all along that the whole market is going to segment. There are going to be multiple mechanisms that people would want, the physicians want, the patients want, and they would benefit from it. That's basically what we're starting to see now, that this is not game over with just the first generation of obesity drugs, but we are going to need additional mechanisms, and that's exactly what we bring to the table. By adding glucagon to GLP-1, we think that really gives, provides some additional differentiation from just GLP-1 alone. The fact that we are seeing profound improvement in serum lipids, very, you know, class-leading liver fat reduction. If you look at this patient population, the first wave of diabetes treatment is really designed for obesity treatment is designed for patients with obesity and diabetes, but there's many more patients that don't have diabetes, but have other comorbidities, such as dyslipidemia and high liver fat content. We think we fit really nicely there. We've been very encouraged. There's lots of interest, as you've seen already from two recent acquisitions, in novel obesity mechanisms and compounds. Glucagon is gonna have a seat at the table. We're seeing that from large pharma, from their internal programs, the data coming out on glucagon. We are very encouraged with our ongoing discussions, and the, the data from MOMENTUM, upcoming data from MOMENTUM, and the fact that we've initiated IMPACT is going to further catalyze those, those discussions. We're very excited about the prospects of having a partner on board before we start phase III development in obesity, sometime next year. Yeah, Yasmin, I'll take your second question about the tirzepatide and the Boehringer Ingelheim Zealand readouts in the first half of next year. I think it's important to point out that tirzepatide has no glucagon activity, the glucagon activity in the Boehringer Ingelheim Zealand compound is pretty minimal. The compound is highly biased to GLP-1. The ratio is 8 to 1, as evidence of that, they're not seeing meaningful effects on serum lipids, for that matter, nor is tirzepatide. That tracks directly to the absence of having glucagon. In contrast, we have glucagon. We're not only seeing very significant reduction in serum lipids, but also liver fat as well. In their non-invasive study, tirzepatide, at the 15 mg dose, their top dose, only achieved a reduction in liver fat content at the end of an entire year of 39%. We think that reflects what I just said about glucagon. Zealand has not come forward with any non-invasive data about their liver fat, but we think it would follow in the same pattern. We still believe that glucagon is key to the rapid reduction of liver fat. We think the rapid reduction of liver fat is important for achieving not only NASH resolution and fibrosis improvement on the biopsies, we think that the results that we get from our Impact trial will significantly exceed those from either of those two compounds in the first half of next year. Thank you so much, team, and really excited on the continued progress. I'll jump back into the queue. Thank you. One moment for our next question. Our next question comes from the line of Roger Song from Jefferies. Great. Congrats for the progress as well. Thank you for taking the question. Maybe a couple questions, mostly related to the obesity. First of all, maybe can you comment your readiness for the phase III for the obesity trial in terms of the dosing and then maybe some of the consideration after you've seen the phase II 24-week data. Admittedly, you're still waiting for the 48-week, but just curious the preparation for the phase III in conjunction with the partnership discussion. That's number one. Number two, very interesting, Vipin, you mentioned this comorbidity with obesity, a pretty high percentage. Just curious, given the very differentiated glucagon addition to the mechanism, how likely you think you can do some creative design for the trial, maybe enrich those comorbidity patients to demonstrate even bigger treatment effect or the benefit for those patients with the comorbidity? Thank you. Absolutely. Scott, you wanna take the comorbidity question first? Yeah, Roger, thanks for the question. Obviously, we're deeply in preparations for phase III, and we have not been public about what those specific plans would be, but we have talked about the fact that based on the prior programs, we think the safety database will be about 5,000 subjects, with about three quarters of those receiving active drug and about one quarter receiving placebo. It appears that it's the size of the safety database that matters. The agency appears to want to study in non-diabetics and diabetics. Beyond that, there's been some options about looking at, for example, osteoarthritis, looking at a comorbidity and the like, and we're in active discussions right now. You know, we've, we've been getting feedback from partners about that as well as what their preferences, would be. as soon as we have additional information about that, we'll, we'll share that with investors. Vipin, did you... Yeah, I mean, a couple of things. First of all, in terms of being phase III ready, our plan is to be phase III ready in the second half of next year. Obviously, we have to wait for the 48-week data before requesting a meeting with the FDA, which we plan to do. We're, you know, putting all the plans in place for that. Again, our goal is to have a partner lined up before we start phase III. From a timing perspective, that kind of fits nicely, gives us the first half of next year to both line up a partner as well as as well as have the phase III ready program as soon as the, you know, as soon as we have the end of phase II meeting with the FDA. In terms of enriching patients for comorbidity, comorbidities, as Scott mentioned, it's going to be a fairly large phase III campaign anyway, so we really don't have to go looking for these patients. These patients are there. I mean, the prevalence of these two comorbidities is even higher than diabetes, so it's not hard to find these patients. So we, you know, we're in a good shape in terms of having access to those patients in the obesity subpopulation, if you want to think of it that way. Scott? Yeah, Roger, what I wanted to add, and I was waiting for Vipin to finish his comments, was that the best place to look at those, that enriched populations is in an outcomes trial, 'cause actually that's the endpoint, right? You wanna make sure that it's adequately powered. As I mentioned in the opening remarks, the SELECT trial is extremely important for showing that obesity improves the outcomes of patients at risk. As I also mentioned in the opening remarks, we think that with comparable weight loss, we will do better than that because of glucagon's effects on serum, lipids, and hepatic fat content. That trial will be enriched with those patients. We think that's probably the best place to analyze those results because of the number of subjects and the power in the trial and what the outcome actually is. That's great. Thanks for all the comments. I really, I really appreciate it. That's it from us. Thank you. One moment for our next question. Our next question comes from the line of Corinne Jenkins from Goldman Sachs. Good morning. This is Craig on for Corinne. I wanted to build on a point that you just highlighted, specifically that about finding a partner to develop pemvidutide. I guess what I'm wondering is, can you describe what your ideal partner would look like? Specifically, are you looking for someone to contribute to the development of NASH and obesity or just individual indications? Absolutely. Good morning, and thank you for the question. I mean, the, the best thing, the best way I can describe it, that we're talking to fairly large universe of companies, all of the companies that you would expect us to be talking to and, and then some. In terms of looking at the indications, we don't believe that a partner would want to split indications given that it's the same molecule, it's the same drug for both NASH and obesity. Yes, our ideal partner would be somebody who is interested in both of these indications. The good news is that they're both metabolic diseases, so we are finding that people are interested in both indications and even additional indications for, for, incretin-based compounds. Overall, you know, we'll, we'll, we, we have flexibility. We can structure the deal in various ways, I think both of these indications, or perhaps all indications, would be included in that partnership. The key for us is to really get the full value for the asset. We are very encouraged with conversations, and we'll keep moving forward. Got it. Thank you very much. Thank you. One moment for our next question. Our next question comes from the line of Mayank Mamtani from B. Riley Securities. Good morning, team. Thanks for taking our questions. A few from us. Staying on this theme of glucagon-based therapeutics being complementary to a number of programs out there, just, I was curious if there's any work underway regarding combinability with SEMA. I assume your NASH phase IIb is, you know, assuming some sort of background rate of, you know, either diabetes or obesity level doses. Not sure if you can comment on what those rates are. Sorry, I haven't been able to dig out your clinical trial design yet on ClinicalTrials.gov. I'm not sure if that's posted there. Then I have a couple of follow-ups. Yeah, Mayank, we believe that pemvidutide would be safe on top of existing GLP-1 therapy. It's something that we've certainly looked at as potentially studying at some point in the future, but our current feeling is that there would be no problem if a physician wanted to combine those therapies using them concomitantly. More importantly, we should see additional benefit of putting pemvidutide over and above, you know, any of the, the baseline diabetes treatments, again, because of the glucagon component and having a direct effect, a direct hepatic effect on hepatic fat. Like, boosting GLP-1 activity should only be helpful, like GIP does. That's right. And then on MOMENTUM, quickly, the, the baseline characteristics there for the full, patient cohort, you know, relative to the interim analysis population cohort that you reported on in March, any, any insight you have there on differences? I was also curious about, you know, there were certain sites that may have contributed to a higher, discontinuation rate. So was there, was there, like, a ratio that you can share what, what the full population versus the interim analysis population looks like in those sites? Yeah, Mayank. We announced when we completed enrollment in MOMENTUM, and I believe that was in the September of 2022. We announced that we had done a comparison of the full population versus the interim analysis population, and that we had made public statements that the demographics were comparable in terms of age, BMI, body weight, gender ratio, and the like. There's been no additional information. That was really a snapshot we took when the trial completed enrollment. Regarding the discontinuation rates of trials, yes, there has been some sites that had out of place rates of discontinuation that clearly were higher than other sites. For example, Dr. Aronne sites had no discontinuations at all. It showed that the careful management of patients really controlled or mitigated the discontinuation rate. Yeah, that is something, and, you know, we've taken a look at those sites and whether they would really be sites that we would consider for future trials. Okay, got it. Have to ask a quick, SELECT CVOT trial question. Obviously, we have to see the full results there, but since, you know, this was a non-type 2 diabetes patient population, and everyone's trying to understand, you know, the HbA1c independent mechanisms at work there. I was just curious about the CRP biomarker. You know, as we know, the inflammatory underlying state that can help with outcomes. Is that a marker you're looking at, in, in your NASH study that is starting out or, or even in the obesity study, if you'd report on that? We hope to have that information in the future. We don't have information to share at this point. Okay. Last one for Rich, quickly. On the R&D spend coming down quarter-over-quarter, obviously, as you ramp up with this NASH study scaling up, we should, we should, have that sort of trend back up. I was just curious if any manufacturing capacity related investments, that also kind of feed into that, 'cause, you know, obviously you are probably making sure that you are making, you know, investments for phase III-ready supply of the drug. Yeah, all that, all that is true, Mayank. The spend did come down as some of the other trials, the NAFL trials we ran last year, and the diabetes drug-drug interaction trial rolled off. Q2 was pretty much just MOMENTUM trial expense, a little bit of investment into the IMPACT trial. Looking at the second half of this year, the IMPACT trial expenditures should increase. You know, as you point out, we also will have some manufacturing expenses to get the phase III materials ready. All that, you know, will probably lead to some increase or, you know, rebound back to the old R&D expenditure rates, but that should be just temporary or temporal as MOMENTUM completes, and patients are rolling off that trial now. You know, as we complete that, there's always a, a big expenditure towards the end of the trial as we do the data analyses and such forth, but that will end up rolling back out in 2025 or 2024, I'm sorry. Understood. Thanks for taking our question. Thank you. One moment for our next question. Our next question comes from the line of Jon Wolleben from JMP. Hey, good morning, and thanks for the update and taking the questions. Two for me. You mentioned expectations for weight loss after 48 weeks, but I was hoping you could talk about what you think you'll see in terms of tolerability, GI adverse events, especially within the context of the trial design. Then also, Scott, you mentioned heart rate a couple of times. Wondering, you know, what you view as that threshold between acceptable and unacceptable heart rate increases for the class. Thanks. Yeah, thanks, Jonathan. Regarding the first, you know, we're still blinded to the data. We certainly are not seeing anything that would indicate that we would have any worsening of any adverse events. We think there's only this prospect of this continuing to get better, but we'll have the data at 48 weeks. One thing to point out as we go into phase III, that there's learnings in phase II. We've seen that with all of the companies. We saw 20% adverse event discontinuation rates with the oral GLP-1 program, the Lilly program. We saw it with the tirzepatide... Excuse me. We saw it with the rezutrid program, and it was also, as we've mentioned in prior calls, seen in other phase II programs. We think that these companies have clearly addressed this, and we think that our dose reduction strategy is something that will really bring this down over the course of time, especially in phase III. Regarding the heart rate increases, it's not really known what the actual threshold is, but one of the things I would point out is the concern that in the retatrutide trial, that heart rate increase is also associated with arrhythmias, and the two could be linked. In the retatrutide phase 1 studies, they were seeing heart rate increases that were quite high, as much as 30 beats per minute early on. The data that they're reporting out is really at the end of the trial. There's a lot more to learn as that data comes out, but I would flip to the positive and say that we're not seeing that with our data. We're not seeing any heart rate increases, we're not seeing any imbalances of arrhythmia, and we really think that that distinguishes us from retatrutide and other compounds in the field. Mechanistically, you'd expect that to happen early on in treatment, so if we didn't see it at 24 weeks, unlikely to see it at 48? That's a difficult question, but there does appear to be higher heart rate increases early on. There appears to be adaptation over the course of time. What's important to understand with regards to, say, those arrhythmias is not that they occurred, but when they occurred during the course of the trial. The trials that are being conducted in phase two are, by clinical development standards, relatively small. They're supposed to be in phase two, but these are the kind of events that come out in outcomes trials when you're studying 15,000 subjects. We feel very comfortable with our cardiovascular safety profile, but, you know, as you start taking any drug with any kind of signal and expanding the population, you may be seeing something in a large outcomes trial, especially one that's a risk-enriched with patients at risk. That's helpful, Scott. Thanks again for taking the questions. Thank you. One moment for our next question. Our next question comes from the line of Patrick Trucchio from H.C. Wainwright. Hi, good morning. Luis here, on for Patrick. Thanks for taking our questions. One question regarding the NASH program and, are 24 weeks enough to see the benefits on NASH resolution and fibrosis improvements? Do you think you can already have some data, preclinical data that could predict that? I have another question on the HepTcell program. Right. Thanks for the question, Luis. We do have preclinical data in animal models of NASH showing fibrosis improvement, and that's been accompanied also by gene expression studies showing reduction in those drivers of late cell activity and fibrosis. Regarding the 24-week endpoint, several companies have shown the ability to achieve NASH resolution and fibrosis improvement at 24 weeks. We believe that with our class-leading liver fat reduction effects and with the link between liver fat reduction and the factors that you just mentioned, we think we have a very high likelihood of achieving success in those endpoints at 24 weeks. It's important to point out that it's not just the magnitude of the effect, it's also how fast you get there. Also not only it's class-leading in terms of overall reduction in liver fat, but the speed of it, very fast reduction in liver fat, we believe gives plenty of time for the liver to heal in 24 weeks. Thank you. That's helpful. Can you discuss the antiviral mechanisms that you believe will be most complementary to the HepTcell? What do you need to see in the HepTcell data to, to have more confidence to move the program forward to a larger trial? Scot Roberts, do you want to take that? On the combination trial, potentially. Sure. Roberts, you want to take that? Absolutely. Yes, you know, the mechanism of, of HepTcell itself, which is an immunotherapeutic, is to stimulate T cells that are able to recognize the HBV virus, and in that way, help clear the virus from the infected cells. As you know, you know, the recent antivirals, siRNAs, monoclonal antibodies against surface antigen, have been very effective at dropping the surface antigen level, but removal of those agents causes a rebound in the in the level of that surface antigen and the immune tolerant state that, that results from that. That's why it's generally believed that the combination of a direct acting antiviral to lower the surface antigen levels and take the pressure of the immune suppression off the immune system, together with an immunotherapy to rev up the now released immune system could be an effective way to treat this disease. We believe that HepTcell, with its ability to stimulate responses against very conserved portions of the HBV polymerase and core antigen, will be an effective immunotherapy that when combined with an effective anti-direct acting antiviral could yield a very interesting effective therapy. As far as what we're expecting in the phase II HepTcell study, the efficacy endpoint is set at the 1 log reduction in the surface antigen. We believe that, that that's readily achievable. Really, any sort of convincing effect of monotherapy with the HepTcell would then align us and prepare us for a follow-on study with the direct acting antiviral. Great. Just a quick follow-up on that. Would you have any other types of analysis on the antigen-presenting side on the potential effect to have a not just a stronger response, but a broader response with the type of CD8+ T cells that are required to clear those infected cells? Well, especially with respect to breath, that's, that's really one of the differentiating aspects of HepTcell. It's, it's the epitopes that we've selected to include in the peptides that constitute HepTcell. With respect to breath, because these epitopes are enlarged in hydrophobic regions and are highly conserved between the different genotypes, we feel that the immune response, which we've demonstrated preclinically to be broad against, you know, subtype, genotypes A through D, would extend through all of the known genotypes right now. That's what the bioinformatics would suggest, and we do have the preclinical data showing a very broad response. Great. Thank you. Thank you. At this time, I would now like to turn the conference back over to Vipin Garg for closing remarks. Thank you. Thank you everyone for participating today. We appreciate the opportunity to share our results and outlook with you, and thank you for your continued interest. Have a nice day. This concludes today's conference call. Thank you for participating. You may now disconnect.